Drug pricing reform has been a political football for several years, with each Donald Trump and Joe Biden championing improvements throughout their presidencies. Little has moved the needle on Capitol Hill, on the other hand, many thanks in portion to the drug industry’s strong lobbyists.

In the most latest example, Democrats attempted to permit Medicare to negotiate drug costs — an fast non-starter for biopharma proponents. Soon after months of negotiation, the measure fell apart in favor of provisions on a tiny subset of medications that handed the Residence but marked a significantly cry from Biden’s guarantees and what many activists experienced hoped for. The bill, included as portion of Biden’s wide social plan agenda, now seems useless just after Democrats failed to secure 50 votes in the Senate.

Continue to keep looking at Endpoints with a absolutely free subscription

Unlock this story promptly and be a part of 126,200+ biopharma professionals studying Endpoints every day — and it truly is absolutely free.

Indicator UP
LOG IN